TDMS Study 05103-04 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL
NTP Experiment-Test: 05103-04 Report: PEIRPT05
Study Type: CHRONIC Date: 05/19/95
Route: DOSED FEED Time: 19:06:50
Facility: Southern Research Institute
Chemical CAS #: 3296-90-0
Lock Date: 02/12/92
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05103-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL Date: 05/19/95
Route: DOSED FEED Time: 19:06:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATD 0.0312% 0.0625% 0.125%
CONTROL
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 8 10 9 10
Early Deaths
Moribund Sacrifice 9 14 14 29
Natural Death 6 6 11 10
Survivors
Terminal Sacrifice 37 30 26 11
Animals Examined Microscopically 60 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (56) (57) (55) (55)
Sarcoma, Metastatic, Mesentery 1 (2%)
Intestine Large, Colon (60) (60) (58) (59)
Hemangioma 1 (2%)
Intestine Large, Rectum (58) (60) (60) (60)
Histiocytic Sarcoma 1 (2%)
Intestine Large, Cecum (60) (60) (58) (60)
Hemangioma 1 (2%)
Intestine Small, Jejunum (57) (59) (58) (57)
Liver (59) (60) (59) (59)
Hepatocellular Carcinoma 4 (7%) 8 (13%) 5 (8%) 1 (2%)
Hepatocellular Carcinoma, Multiple 1 (2%) 2 (3%)
Hepatocellular Adenoma 13 (22%) 9 (15%) 4 (7%) 14 (24%)
Hepatocellular Adenoma, Multiple 3 (5%) 3 (5%) 2 (3%) 3 (5%)
Histiocytic Sarcoma 2 (3%) 2 (3%) 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Mesentery (4) (7) (8) (8)
Sarcoma 1 (13%)
Yolk Sac Carcinoma, Metastatic, Ovary 1 (13%)
Pancreas (59) (60) (58) (58)
Sarcoma, Metastatic, Mesentery 1 (2%)
Sarcoma Stromal, Metastatic, Uterus 1 (2%)
Salivary Glands (60) (60) (60) (60)
Stomach, Forestomach (59) (60) (60) (59)
Squamous Cell Papilloma 1 (2%) 5 (8%) 4 (7%)
Stomach, Glandular (59) (60) (58) (59)
Sarcoma Stromal, Metastatic, Uterus 1 (2%)
Tongue (1)
Squamous Cell Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05103-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL Date: 05/19/95
Route: DOSED FEED Time: 19:06:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATD 0.0312% 0.0625% 0.125%
CONTROL
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (60) (60) (60)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (59) (60) (60) (59)
Sarcoma, Metastatic, Skin 1 (2%)
Capsule, Carcinoma 1 (2%)
Adrenal Medulla (59) (60) (60) (59)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (59) (60) (58) (59)
Adenoma 1 (2%) 3 (5%) 2 (3%) 2 (3%)
Pituitary Gland (58) (58) (57) (56)
Pars Distalis, Adenoma 4 (7%) 8 (14%) 3 (5%) 5 (9%)
Pars Distalis, Carcinoma 1 (2%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (59) (60) (60) (59)
Follicular Cell, Adenoma 3 (5%) 1 (2%) 3 (5%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (2)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (59) (59) (60) (57)
Adenoma 1 (2%) 1 (2%)
Carcinoma 1 (2%)
Granulosa Cell Tumor Benign 1 (2%) 1 (2%)
Luteoma 2 (3%)
Yolk Sac Carcinoma 1 (2%)
Bilateral, Adenoma 1 (2%)
Uterus (60) (60) (60) (60)
Carcinoma 1 (2%) 2 (3%) 2 (3%)
Deciduoma Benign 1 (2%)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Polyp Adenomatous 1 (2%)
Polyp Stromal 3 (5%) 1 (2%) 1 (2%)
Sarcoma Stromal 1 (2%) 2 (3%)
Vagina (1)
Squamous Cell Papilloma 1 (100%)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 05103-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL Date: 05/19/95
Route: DOSED FEED Time: 19:06:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATD 0.0312% 0.0625% 0.125%
CONTROL
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (60) (60) (60)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymph Node (9) (12) (6) (9)
Mediastinal, Sarcoma, Metastatic, Skin 1 (17%)
Renal, Histiocytic Sarcoma 1 (8%)
Renal, Sarcoma, Metastatic, Skin 1 (11%)
Lymph Node, Mandibular (56) (56) (59) (56)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mesenteric (57) (58) (55) (58)
Histiocytic Sarcoma 3 (5%) 2 (4%) 1 (2%)
Sarcoma Stromal, Metastatic, Uterus 1 (2%)
Spleen (59) (60) (59) (60)
Hemangioma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Thymus (54) (57) (55) (52)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (59) (60) (59) (59)
Adenoacanthoma 1 (2%)
Carcinoma 1 (2%) 2 (3%)
Carcinoma, Multiple 1 (2%)
Skin (59) (60) (60) (60)
Squamous Cell Papilloma 1 (2%) 1 (2%)
Sebaceous Gland, Carcinoma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%)
Subcutaneous Tissue, Fibrous Histiocytoma 1 (2%)
Subcutaneous Tissue, Hemangioma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 2 (3%)
Subcutaneous Tissue, Sarcoma 4 (7%) 11 (18%)
Subcutaneous Tissue, Sarcoma, Multiple 1 (2%)
Subcutaneous Tissue, Schwannoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05103-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL Date: 05/19/95
Route: DOSED FEED Time: 19:06:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATD 0.0312% 0.0625% 0.125%
CONTROL
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (60) (60) (60) (60)
Osteosarcoma 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Peripheral Nerve (1) (1) (1) (1)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60) (60) (60)
Alveolar/Bronchiolar Adenoma 3 (5%) 3 (5%) 7 (12%) 17 (28%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 2 (3%) 2 (3%)
Alveolar/Bronchiolar Carcinoma 3 (5%) 2 (3%) 5 (8%) 4 (7%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%) 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%) 2 (3%) 3 (5%) 1 (2%)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Carcinoma, Metastatic, Adrenal Cortex 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (3%) 2 (3%) 1 (2%)
Histiocytic Sarcoma 2 (3%) 2 (3%) 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (22) (32) (31) (40)
Adenoma 3 (14%) 7 (22%) 8 (26%) 18 (45%)
Carcinoma 1 (5%) 6 (19%) 5 (16%) 7 (18%)
Bilateral, Adenoma 1 (3%)
Zymbal's Gland (1)
Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (59) (60) (60) (59)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Urinary Bladder (59) (60) (59) (60)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(60) *(60)
Histiocytic Sarcoma 1 (2%) 4 (7%) 2 (3%) 1 (2%)
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05103-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL Date: 05/19/95
Route: DOSED FEED Time: 19:06:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATD 0.0312% 0.0625% 0.125%
CONTROL
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS - cont
Multiple Organs *(60) *(60) *(60) *(60)
Lymphoma Malignant Lymphocytic 2 (3%) 1 (2%) 1 (2%)
Lymphoma Malignant Mixed 3 (5%) 7 (12%) 7 (12%) 3 (5%)
Lymphoma Malignant Undifferentiated Cell 3 (5%) 1 (2%)
____________________________________________________________________________________________________________________________________
Page 6
NTP Experiment-Test: 05103-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL Date: 05/19/95
Route: DOSED FEED Time: 19:06:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATD 0.0312% 0.0625% 0.125%
CONTROL
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 38 43 46 49
Total Primary Neoplasms 54 80 78 120
Total Animals with Benign Neoplasms 28 30 31 41
Total Benign Neoplasms 37 43 41 72
Total Animals with Malignant Neoplasms 17 32 31 36
Total Malignant Neoplasms 17 37 37 48
Total Animals with Metastatic Neoplasms 3 6 7 4
Total Metastatic Neoplasm 4 8 8 9
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 05103-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL Date: 05/19/95
Route: DOSED FEED Time: 19:06:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATD 0.0312% 0.0625% 0.125%
CONTROL
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 10 9 10 10
Early Deaths
Natural Death 5 3 4 5
Moribund Sacrifice 3 12 11 13
Accidently Killed 1
Survivors
Terminal Sacrifice 42 36 35 30
Missing 1
Animals Examined Microscopically 60 60 60 59
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (58) (53) (59) (52)
Fibrous Histiocytoma 1 (2%)
Hepatoblastoma, Metastatic, Liver 1 (2%)
Intestine Large, Cecum (59) (58) (58) (58)
Intestine Small, Duodenum (59) (59) (59) (56)
Intestine Small, Jejunum (59) (58) (59) (58)
Carcinoma 2 (3%)
Intestine Small, Ileum (58) (57) (57) (58)
Carcinoma 1 (2%)
Liver (59) (60) (59) (59)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Cholangiocarcinoma 1 (2%)
Hemangioma 1 (2%) 1 (2%)
Hemangiosarcoma 1 (2%) 2 (3%) 2 (3%)
Hepatoblastoma 1 (2%)
Hepatocellular Carcinoma 11 (19%) 15 (25%) 14 (24%) 9 (15%)
Hepatocellular Carcinoma, Multiple 2 (3%) 1 (2%)
Hepatocellular Adenoma 16 (27%) 19 (32%) 12 (20%) 12 (20%)
Hepatocellular Adenoma, Multiple 6 (10%) 5 (8%) 8 (14%) 9 (15%)
Histiocytic Sarcoma 2 (3%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 2 (3%)
Mesentery (3) (2) (1) (4)
Hemangiosarcoma 1 (25%)
Hepatoblastoma, Metastatic, Liver 1 (50%)
Histiocytic Sarcoma 1 (50%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (25%)
Page 8
NTP Experiment-Test: 05103-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL Date: 05/19/95
Route: DOSED FEED Time: 19:06:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATD 0.0312% 0.0625% 0.125%
CONTROL
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Pancreas (59) (60) (59) (59)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Pharynx (1)
Squamous Cell Papilloma 1 (100%)
Stomach, Forestomach (59) (60) (60) (58)
Squamous Cell Carcinoma 1 (2%) 2 (3%)
Squamous Cell Papilloma 3 (5%) 2 (3%) 3 (5%)
Stomach, Glandular (59) (60) (59) (58)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (60) (60) (59)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (58) (60) (60) (59)
Adenoma 1 (2%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Histiocytic Sarcoma 1 (2%)
Capsule, Adenoma 1 (2%)
Adrenal Medulla (59) (59) (60) (59)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (59) (59) (59) (59)
Adenoma 1 (2%) 1 (2%) 1 (2%) 2 (3%)
Pituitary Gland (57) (54) (59) (54)
Pars Distalis, Carcinoma 1 (2%)
Thyroid Gland (59) (60) (59) (59)
Follicular Cell, Adenoma 3 (5%) 4 (7%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 05103-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL Date: 05/19/95
Route: DOSED FEED Time: 19:06:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATD 0.0312% 0.0625% 0.125%
CONTROL
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (59) (60) (60) (59)
Histiocytic Sarcoma 1 (2%)
Preputial Gland (58) (58) (59) (58)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Seminal Vesicle (59) (60) (60) (59)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Testes (59) (60) (60) (59)
Hemangioma 1 (2%)
Interstitial Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (59) (60) (60) (59)
Hemangiosarcoma 2 (3%)
Histiocytic Sarcoma 1 (2%)
Lymph Node (3) (3) (5) (7)
Mediastinal, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (20%)
Lymph Node, Mandibular (56) (58) (59) (55)
Lymph Node, Mesenteric (58) (58) (59) (58)
Histiocytic Sarcoma 2 (3%)
Spleen (59) (60) (59) (59)
Hemangiosarcoma 3 (5%)
Histiocytic Sarcoma 1 (2%)
Thymus (53) (57) (50) (52)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (60) (60) (60) (59)
Mast Cell Tumor Benign 1 (2%)
Squamous Cell Papilloma 1 (2%)
Sebaceous Gland, Adenoma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma 2 (3%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 05103-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL Date: 05/19/95
Route: DOSED FEED Time: 19:06:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATD 0.0312% 0.0625% 0.125%
CONTROL
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1) (1)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (100%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (60) (60) (60) (59)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60) (60) (59)
Alveolar/Bronchiolar Adenoma 14 (23%) 5 (8%) 12 (20%) 11 (19%)
Alveolar/Bronchiolar Adenoma, Multiple 4 (7%) 10 (17%)
Alveolar/Bronchiolar Carcinoma 3 (5%) 6 (10%) 8 (13%) 9 (15%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%) 3 (5%)
Carcinoma, Metastatic, Harderian Gland 1 (2%) 1 (2%)
Hepatoblastoma, Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (3%) 5 (8%) 3 (5%) 3 (5%)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Nose (59) (60) (60) (59)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (26) (31) (33) (36)
Adenoma 3 (12%) 6 (19%) 12 (36%) 12 (33%)
Carcinoma 1 (4%) 1 (3%) 4 (12%) 3 (8%)
Bilateral, Adenoma 1 (3%) 9 (25%)
Bilateral, Carcinoma 1 (3%)
Zymbal's Gland (1)
Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
Page 11
NTP Experiment-Test: 05103-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL Date: 05/19/95
Route: DOSED FEED Time: 19:06:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATD 0.0312% 0.0625% 0.125%
CONTROL
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (59) (60) (60) (59)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Renal Tubule, Adenoma 3 (5%) 2 (3%)
Urinary Bladder (59) (60) (59) (59)
Hemangiosarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(60) *(59)
Histiocytic Sarcoma 2 (3%)
Lymphoma Malignant Lymphocytic 1 (2%)
Lymphoma Malignant Mixed 2 (3%) 2 (3%) 6 (10%) 3 (5%)
Lymphoma Malignant Undifferentiated Cell 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 12
NTP Experiment-Test: 05103-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL Date: 05/19/95
Route: DOSED FEED Time: 19:06:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATD 0.0312% 0.0625% 0.125%
CONTROL
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 43 47 51 53
Total Primary Neoplasms 63 90 92 116
Total Animals with Benign Neoplasms 36 33 44 49
Total Benign Neoplasms 42 47 56 77
Total Animals with Malignant Neoplasms 17 32 24 33
Total Malignant Neoplasms 21 43 36 39
Total Animals with Metastatic Neoplasms 3 6 4 7
Total Metastatic Neoplasm 5 11 4 19
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 13
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------